Top

Published in:

01-06-2018 | Original Article

Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients

Authors: Silvia Park, Hangseok Choi, Hee Je Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Sung-Hyun Kim, Yeung-Chul Mun, Chul Won Jung, Dennis (Dong Hwan) Kim

Published in: Annals of Hematology | Issue 6/2018

Abstract

The present study attempted to build a single nucleotide polymorphism (SNP)-based risk model for predicting overall survival (OS) and event-free survival (EFS) in patients with core binding factor acute myeloid leukemia (CBF-AML). Adopting genome-wide SNP array using Affymetrix SNP array 6.0, we analyzed 868,157 SNPs with respect to OS and EFS in 104 patients with CBF-AML. Significant SNPs were identified from single SNP analysis. The risk model was constructed with incorporation of six SNPs and three clinical factors (age, c-kit exon 17 mutation, and LDH) for OS and six SNPs and three clinical factors (age, WBC, and LDH) for EFS. The model was further defined into low- and high-risk groups based on risk scores. The median age was 39 years, and the subgroup of t(8;21) and inv(16) or t(16;16) was assessed in 68 (65.4%) and 36 patients (34.6%). Finally, six SNPs per each OS (rs4353685, rs4908185, rs7709207, rs12034, rs1554844, and rs17241868) and EFS (rs13385610, rs11210617, rs11169282, rs7709207, rs4438401, and rs16894846) were incorporated into the risk model. OS was significantly different in favor of the low risk group (80.4 ± 8.4%) compared to the high-risk group (22.0 ± 7.3% at 3 years; p = 8.75 × 10^− 13; HR 8.67). For EFS, there was also a significant difference between the low- (75.0 ± 5.8%) versus high-risk group (17.1 ± 6.3% at 3 years; p = 5.95 × 10^− 13; HR 7.67). A genome-wide SNP-based risk model can stratify CBF-AML patients according to their OS and EFS in 104 patients.

Available only for authorised users

Kumar CC (2011) Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2(2):95–107. https://doi.org/10.1177/1947601911408076 CrossRefPubMedPubMedCentral

Martens JH, Stunnenberg HG (2010) The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 584(12):2662–2669. https://doi.org/10.1016/j.febslet.2010.04.002 CrossRefPubMed

Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer, Leukemia Group B (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336. https://doi.org/10.1182/blood-2002-03-0772 CrossRefPubMed

Mrozek K, Radmacher MD, Bloomfield CD, Marcucci G (2009) Molecular signatures in acute myeloid leukemia. Curr Opin Hematol 16(2):64–69. https://doi.org/10.1097/MOH.0b013e3283257b42 CrossRefPubMedPubMedCentral

Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80(7):1825–1831PubMed

Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, Dohner H, German-Austrian AMLSG (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108(10):3280–3288. https://doi.org/10.1182/blood-2006-04-014324 CrossRefPubMed

Paschka P, Dohner K (2013) Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematology Am Soc Hematol Educ Program 2013(1):209–219. https://doi.org/10.1182/asheducation-2013.1.209 PubMed

Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23(24):5705–5717. https://doi.org/10.1200/JCO.2005.15.610 CrossRefPubMed

Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Dohner K, Ganser A, Dohner H, Heil G (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22(18):3741–3750. https://doi.org/10.1200/JCO.2004.03.012 CrossRefPubMed

10.

Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C, Acute Leukemia French A, Leucemies Aigues Myeloblastiques de l'Enfant Cooperative G (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20(6):965–970. https://doi.org/10.1038/sj.leu.2404188 CrossRefPubMed

11.

Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH, L/Mds Working Party KSoH (2013) KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol 92(2):163–171. https://doi.org/10.1007/s00277-012-1580-5 CrossRefPubMed

12.

Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12):2372–2379. https://doi.org/10.1182/blood-2009-09-241075 CrossRefPubMedPubMedCentral

13.

Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, Gari MA, Peake IR, Lowenberg B, Reilly JT (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121(5):775–777. https://doi.org/10.1046/j.1365-2141.2003.04362.x CrossRefPubMed

14.

Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Kohne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Gotze K, Horst HA, Ringhoffer M, Lubbert M, Wattad M, Salih HR, Kundgen A, Dohner H, Dohner K (2013) Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 121(1):170–177. https://doi.org/10.1182/blood-2012-05-431486 CrossRefPubMed

15.

Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM (1996) Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Semin Hematol 33(4 Suppl 3):24–29PubMed

16.

Kim ST, Jung CW, Lee J, Kwon JM, Oh SY, Park BB, Lee HR, Kim HJ, Kim K, Kim WS, Ahn JS, Kang WK, Park K (2007) Postremission therapy for acute myeloid leukemia in the first remission. Leuk Lymphoma 48(5):937–943. https://doi.org/10.1080/10428190701223309 CrossRefPubMed

17.

Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642–4649. https://doi.org/10.1200/jco.2003.04.036 CrossRefPubMed

18.

Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P (2007) Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109(12):5439–5446. https://doi.org/10.1182/blood-2006-11-058040 CrossRefPubMedPubMedCentral

19.

Choi H, Jung C, Sohn SK, Kim S, Kim HJ, Kim YK, Kim T, Zhang Z, Shin ES, Lee JE, Moon JH, Kim SH, Kim KH, Mun YC, Kim H, Park J, Kim J, Kim D (2013) Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. Br J Haematol 163(1):62–71. https://doi.org/10.1111/bjh.12492 CrossRefPubMed

20.

Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedeu JF, Montserrat E, Sierra J, Cetlam (2006) Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107(12):4871–4879. https://doi.org/10.1182/blood-2005-08-3272 CrossRefPubMed

21.

Kuptsova N, Kopecky KJ, Godwin J, Anderson J, Hoque A, Willman CL, Slovak ML, Ambrosone CB (2007) Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 109(9):3936–3944. https://doi.org/10.1182/blood-2006-05-022111 CrossRefPubMed

22.

Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S (2011) Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG. Blood 118(17):4561–4566. https://doi.org/10.1182/blood-2011-04-348888 CrossRefPubMedPubMedCentral

23.

Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 28(14):2356–2364. https://doi.org/10.1200/JCO.2009.27.6899 CrossRefPubMed

24.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Gohring G, Schlegelberger B, Dohner K, Ottmann O, Lubbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Dohner H, Heil G, Ganser A, Krauter J (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28(4):578–585. https://doi.org/10.1200/JCO.2009.23.0342 CrossRefPubMed

25.

Keenan J, Joyce H, Aherne S, O’Dea S, Doolan P, Lynch V, Clynes M (2012) Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line. Exp Cell Res 318(5):593–602. https://doi.org/10.1016/j.yexcr.2012.01.012 CrossRefPubMed

26.

Kim YN, Koo KH, Sung JY, Yun UJ, Kim H (2012) Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2012:306879. https://doi.org/10.1155/2012/306879 CrossRefPubMedPubMedCentral

27.

Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304):1320–1323. https://doi.org/10.1126/science.275.5304.1320 CrossRefPubMed

28.

Saito K, Sakaguchi M, Iioka H, Matsui M, Nakanishi H, Huh NH, Kondo E (2014) Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells. Oncogene 33(10):1274–1286. https://doi.org/10.1038/onc.2013.66 CrossRefPubMed

29.

Paoli P, Giannoni E, Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833(12):3481–3498. https://doi.org/10.1016/j.bbamcr.2013.06.026 CrossRefPubMed

30.

Greim H, Kaden DA, Larson RA, Palermo CM, Rice JM, Ross D, Snyder R (2014) The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci 1310(1):7–31. https://doi.org/10.1111/nyas.12362 CrossRefPubMedPubMedCentral

31.

Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, Alexander WS, Lowe SW, Robb L, Strasser A (2012) Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26(2):120–125. https://doi.org/10.1101/gad.182980.111 CrossRefPubMedPubMedCentral

32.

Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7(4):549–556. https://doi.org/10.1158/1541-7786.MCR-08-0358 CrossRefPubMedPubMedCentral

33.

Bondar VM, McConkey DJ (2002) Anoikis is regulated by BCL-2-independent pathways in human prostate carcinoma cells. Prostate 51(1):42–49. https://doi.org/10.1002/pros.10070 CrossRefPubMed

34.

Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y, Chanvorachote P (2010) Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Apoptosis 15(5):574–585. https://doi.org/10.1007/s10495-010-0461-4 CrossRefPubMed

35.

Galante JM, Mortenson MM, Bowles TL, Virudachalam S, Bold RJ (2009) ERK/BCL-2 pathway in the resistance of pancreatic cancer to anoikis. J Surg Res 152(1):18–25. https://doi.org/10.1016/j.jss.2008.05.017 CrossRefPubMed

36.

Wongpankam E, Chunhacha P, Pongrakhananon V, Sritularak B, Chanvorachote P (2012) Artonin E mediates MCL1 down-regulation and sensitizes lung cancer cells to anoikis. Anticancer Res 32:5343–5351PubMed

37.

Mesicek J, Lee H, Feldman T, Jiang X, Skobeleva A, Berdyshev EV, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2010) Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal 22(9):1300–1307. https://doi.org/10.1016/j.cellsig.2010.04.006 CrossRefPubMedPubMedCentral

38.

Levy M, Futerman AH (2010) Mammalian ceramide synthases. IUBMB Life 62:347–356. https://doi.org/10.1002/iub.319 CrossRefPubMedPubMedCentral

39.

Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 281(35):25001–25005. https://doi.org/10.1074/jbc.R600010200 CrossRefPubMed

40.

Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA, Ogretmen B (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6(2):712–722. https://doi.org/10.1158/1535-7163.MCT-06-0558 CrossRefPubMed

41.

Mojakgomo R, Mbita Z, Dlamini Z (2015) Linking the ceramide synthases (CerSs) 4 and 5 with apoptosis, endometrial and colon cancers. Exp Mol Pathol 98(3):585–592. https://doi.org/10.1016/j.yexmp.2015.03.019 CrossRefPubMed

42.

Yun SH, Park ES, Shin SW, Na YW, Han JY, Jeong JS, Shastina VV, Stonik VA, Park JI, Kwak JY (2012) Stichoposide C induces apoptosis through the generation of ceramide in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 18(21):5934–5948. https://doi.org/10.1158/1078-0432.CCR-12-0655 CrossRefPubMed

43.

Casson L, Howell L, Mathews LA, Ferrer M, Southall N, Guha R, Keller JM, Thomas C, Siskind LJ, Beverly LJ (2013) Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. PLoS One 8(1):e54525. https://doi.org/10.1371/journal.pone.0054525 CrossRefPubMedPubMedCentral

44.

Chen L, Luo LF, Lu J, Li L, Liu YF, Wang J, Liu H, Song H, Jiang H, Chen SJ, Luo C, Li KK (2014) FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. PLoS One 9(7):e103033. https://doi.org/10.1371/journal.pone.0103033 CrossRefPubMedPubMedCentral

45.

Parihar R, Mishra R, Singh SK, Jayalakshmi S, Mehndiratta MM, Ganesh S (2014) Association of the GRM4 gene variants with juvenile myoclonic epilepsy in an Indian population. J Genet 93(1):193–197. https://doi.org/10.1007/s12041-014-0334-7 CrossRefPubMed

46.

Muhle H, von Spiczak S, Gaus V, Kara S, Helbig I, Hampe J, Franke A, Weber Y, Lerche H, Kleefuss-Lie AA, Elger CE, Schreiber S, Stephani U, Sander T (2010) Role of GRM4 in idiopathic generalized epilepsies analysed by genetic association and sequence analysis. Epilepsy Res 89(2-3):319–326. https://doi.org/10.1016/j.eplepsyres.2010.02.004 CrossRefPubMed

47.

Jiang C, Chen H, Shao L, Dong Y (2014) GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population. Med Oncol 31(7):50. https://doi.org/10.1007/s12032-014-0050-4 CrossRefPubMedPubMedCentral

48.

Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J, Kashyap M, Hu P, Maiuri T, Narala SR, Stambolic V, Squire J, Penninger J, Sanchez O, Triche TJ, Wood GA, Kirschner LS, Khokha R (2010) Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 120(9):3310–3325. https://doi.org/10.1172/JCI42391 CrossRefPubMedPubMedCentral

49.

Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos SG, Robinson-White A, Lenherr SM, Weinberg FD, Claflin ES, Batista D, Bourdeau I, Voutetakis A, Sandrini F, Meoli EM, Bauer AJ, Cho-Chung YS, Bornstein SR, Carney JA, Stratakis CA (2004) A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet 41(12):923–931. https://doi.org/10.1136/jmg.2004.028043 CrossRefPubMedPubMedCentral

50.

Shankar DB, Cheng JC, Kinjo K, Federman N, Moore TB, Gill A, Rao NP, Landaw EM, Sakamoto KM (2005) The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 7(4):351–362. https://doi.org/10.1016/j.ccr.2005.02.018 CrossRefPubMed

51.

Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA (2015) Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab 114(3):397–402. https://doi.org/10.1016/j.ymgme.2014.11.017 CrossRefPubMed

52.

Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM (2010) Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 10(4):384–391. https://doi.org/10.2174/156800910791208535 CrossRefPubMedPubMedCentral

Title: Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients
Authors: Silvia Park
Hangseok Choi
Hee Je Kim
Jae-Sook Ahn
Hyeoung-Joon Kim
Sung-Hyun Kim
Yeung-Chul Mun
Chul Won Jung
Dennis (Dong Hwan) Kim
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 6/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3260-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience

Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma

Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation

Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations

Adult T cell leukemia/lymphoma with different pathological features in each tumor site

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page